Castleview Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.09M Buy
909
+214
+31% +$219K 0.48% 47
2026
Q1
$639K Sell
695
-107
-13% -$108K 0.33% 69
2025
Q4
$862K Sell
802
-6
-0.7% -$5.74K 0.43% 50
2025
Q3
$617K Sell
808
-20
-2% -$14.9K 0.33% 61
2025
Q2
$645K Buy
828
+78
+10% +$60.6K 0.41% 55
2025
Q1
$619K Buy
750
+53
+8% +$44.1K 0.42% 62
2024
Q4
$542K Buy
697
+301
+76% +$249K 0.29% 84
2024
Q3
$351K Buy
396
+123
+45% +$111K 0.2% 121
2024
Q2
$247K Sell
273
-107
-28% -$85.6K 0.14% 145
2024
Q1
$296K Hold
380
0.17% 137
2023
Q4
$222K Buy
380
+192
+102% +$112K 0.16% 130
2023
Q3
$101K Buy
188
+4
+2% +$2.06K 0.09% 177
2023
Q2
$86.3K Hold
184
0.08% 196
2023
Q1
$63.2K Sell
184
-89
-33% -$30K 0.06% 239
2022
Q4
$99.9K Hold
273
0.1% 161
2022
Q3
$88K Sell
273
-576
-68% -$182K 0.08% 180
2022
Q2
$39.7K Buy
849
+649
+325% +$195K 0.03% 331
2022
Q1
$57K Buy
+200
New +$51.5K 0.04% 331
2021
Q2
$2K Buy
+10
New +$2.01K ﹤0.01% 862

Other funds holding LLY

Castleview Partners's LLY Position: Q2 2026 in Review

Castleview Partners increased its Eli Lilly (LLY) stake by 31% in Q2 2026, buying an estimated $219K and bringing the position to 909 shares worth $1.09M. The position accounts for 0.48% of the portfolio, ranked #47.

Castleview Partners first reported a position in LLY in Q2 2021 and has held it in 19 quarters since. 1,734 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Castleview Partners held 909 shares of Eli Lilly worth $1.09M as of Q2 2026.
  • Castleview Partners bought 214 Eli Lilly shares in Q2 2026, an estimated $219K.
  • Eli Lilly made up 0.48% of Castleview Partners's portfolio in Q2 2026, its #47 holding.
  • Castleview Partners first reported a position in Eli Lilly in Q2 2021 and has held it in 19 quarters since.
  • 1,734 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Castleview Partners's 13F filing for Q2 2026, filed 20 Jul 2026.